CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 165 enrolled
Drug / intervention
Pneumococcal 13-valent Conjugate Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04080531
NCT04080531Phase 4Completed
CompareCT.gov

Influenza Vaccination in Plasma Cell Dyscrasias

Emory University·interventional·Posted Sep 6, 2019·Updated Feb 28, 2025

In Brief

A Phase 4 clinical trial evaluating Pneumococcal 13-valent Conjugate Vaccine and Trivalent Influenza Vaccine for Plasma Cell Neoplasm. Completed, enrolled 165 participants across 2 sites.

Detailed Summary

This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlasma Cell Neoplasm
CountriesUnited States
CollaboratorsSanofi, National Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartOct 18, 2019
Primary CompletionMay 11, 2021
Study CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.8 years ago

Interventions

Pneumococcal 13-valent Conjugate Vaccinebiological

Given IM

Trivalent Influenza Vaccinebiological

Given IM